Percutaneous Left Atrial Appendage Occlusion: What the Practising Physician Should Know

Pierluigi Merella1, Giuseppe Talanas1, Giovanni Lorenzoni1

  • 1Department of Cardiology, Azienda Ospedaliero Universitaria di Sassari Sassari, Italy.

European Cardiology
|October 20, 2023
PubMed

Insights

Non-valvular atrial fibrillation (AF) increases stroke risk. Left atrial appendage occlusion (LAAO) offers a non-drug alternative for patients unable to take oral anticoagulants due to bleeding risks.

Area of Science:

  • Cardiology
  • Medical Devices
  • Interventional Procedures

Background:

  • Non-valvular atrial fibrillation (AF) is a prevalent condition linked to a higher risk of thromboembolic events.
  • Oral anticoagulant therapy (OAT) is standard for AF management but contraindicated in some patients due to bleeding risks.
  • The left atrial appendage is a primary source of thrombi in AF, prompting alternative stroke prevention strategies.

Purpose of the Study:

  • To review current understanding and clinical considerations for Left Atrial Appendage Occlusion (LAAO).
  • To highlight LAAO as a non-pharmacological option for stroke risk reduction in specific AF patient populations.

Main Methods:

  • This review synthesizes current literature and clinical perspectives on LAAO procedures.
  • Focuses on LAAO as an alternative to OAT for patients with contraindications.

Main Results:

  • Left atrial appendage occlusion (LAAO) is an emerging, effective alternative for cardioembolic event prevention.
  • The demand for LAAO procedures is rapidly increasing, indicating growing clinical adoption.

Conclusions:

  • LAAO is a viable, non-pharmacological strategy for patients with non-valvular AF and contraindications to OAT.
  • Clinicians should consider LAAO when managing high-risk AF patients who cannot tolerate anticoagulation.